1. Home
  2. BBIO vs FAF Comparison

BBIO vs FAF Comparison

Compare BBIO & FAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
    SELLHOLDBUYas of 8 hours ago
  • FAF
    SELLHOLDBUYas of 8 hours ago
  • Stock Information
  • Founded
  • BBIO 2015
  • FAF 1889
  • Country
  • BBIO United States
  • FAF United States
  • Employees
  • BBIO N/A
  • FAF N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • FAF Specialty Insurers
  • Sector
  • BBIO Health Care
  • FAF Finance
  • Exchange
  • BBIO Nasdaq
  • FAF Nasdaq
  • Market Cap
  • BBIO 6.3B
  • FAF 6.7B
  • IPO Year
  • BBIO 2019
  • FAF N/A
  • Fundamental
  • Price
  • BBIO $34.04
  • FAF $64.65
  • Analyst Decision
  • BBIO Strong Buy
  • FAF Buy
  • Analyst Count
  • BBIO 12
  • FAF 4
  • Target Price
  • BBIO $52.64
  • FAF $74.50
  • AVG Volume (30 Days)
  • BBIO 2.6M
  • FAF 785.1K
  • Earning Date
  • BBIO 05-01-2025
  • FAF 04-23-2025
  • Dividend Yield
  • BBIO N/A
  • FAF 3.33%
  • EPS Growth
  • BBIO N/A
  • FAF N/A
  • EPS
  • BBIO N/A
  • FAF 1.26
  • Revenue
  • BBIO $221,902,000.00
  • FAF $6,128,100,000.00
  • Revenue This Year
  • BBIO $12.42
  • FAF $16.46
  • Revenue Next Year
  • BBIO $123.19
  • FAF $10.16
  • P/E Ratio
  • BBIO N/A
  • FAF $51.40
  • Revenue Growth
  • BBIO 2285.27
  • FAF 2.08
  • 52 Week Low
  • BBIO $21.62
  • FAF $51.60
  • 52 Week High
  • BBIO $39.47
  • FAF $70.92
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 49.34
  • FAF 48.47
  • Support Level
  • BBIO $32.83
  • FAF $65.09
  • Resistance Level
  • BBIO $37.06
  • FAF $67.07
  • Average True Range (ATR)
  • BBIO 1.56
  • FAF 1.11
  • MACD
  • BBIO -0.08
  • FAF 0.02
  • Stochastic Oscillator
  • BBIO 39.44
  • FAF 20.92

Stock Price Comparison Chart: BBIO vs FAF

BBIO
FAF
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April0102030405060708090BBIO VS FAF

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About FAF First American Corporation (New)

First American Financial Corp is a financial services business providing insurance through segments: Title insurance and related services segment include real estate insurance, property closing services, third-party handling of real estate funds (escrow), risk mitigation, real estate data products, and related real estate transaction services; The home warranty segment provides residential service contracts that cover residential systems, such as heating and air conditioning systems, and certain appliances against failures that occur as the result of normal usage during the coverage period; and The corporate segment includes investments in venture-stage companies, certain financing facilities and corporate services supporting the company's business operations.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use